Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 16 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				21 and over				Pharmaceutical / Industry				VEG105192 NCT00334282


2.		GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				21 and over				Pharmaceutical / Industry				VEG102616 NCT00244764

Last Modified: 8/7/2007 First Published: 2/10/2006


3.		Phase II Study of GW786034 in Patients With Relapsed or Refractory Advanced or Metastatic Soft Tissue Sarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Other, Pharmaceutical / Industry				EORTC-62043 GSK-EORTC-62043, EUDRACT-2004-004378-10, NCT00297258


4.		Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				21 and over				Pharmaceutical / Industry				VEG20006 NCT00256880


5.		A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				21 and over				Pharmaceutical / Industry				104450 VEG104450, NCT00281632


6.		Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				21 and over				Pharmaceutical / Industry				VEG20007 NCT00347919


7.		Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				21 and over				Pharmaceutical / Industry				VEG105290 NCT00367679


8.		Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				VEG105281 NCT00430781

Last Modified: 10/10/2008 First Published: 4/2/2007


9.		Phase II Study of Pazopanib Hydrochloride in Patients With Recurrent Glioblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				NABTC-0602 NABTC-06-02, NCT00459381, NCI-07-C-0138


10.		Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				109609 NCT00549328

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute